Contemporary medicine is shifting towards person rather than disease-oriented care.1With increasing life expectancy and the ageing of baby boomers, the proportion over 60 years is growing faster than the overall population, with worldwide estimates reaching 2 billion by 2050 (http://www.un.org/esa/population/publications/ worldageing19502050).2 In parallel, acute coronary syndromes (ACS) and atrial fibrillation (AF)—the most frequent indications for dual platelet inhibition or anticoagulation—occur mostly in older patients.2 – 6 There is general agreement that people ≥75 years can be defined ‘elderly’; however, cutoffs as low as 65 years have been applied to important clinical datasets and risk scores.3,7 – 10

Andreotti, F., Rocca, B., Husted, S., Ajjan, R., Ten Berg, J., Cattaneo, M., Collet, J., De Caterina, R., Fox, K., Halvorsen, S., Huber, K., Hylek, E., Lip, G., Montalescot, G., Morais, J., Patrono, C., Verheugt, F., Wallentin, L., Weiss, T., Storey, R., Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis, <<EUROPEAN HEART JOURNAL>>, 2015; 36 (46): 3238-3249. [doi:10.1093/eurheartj/ehv304] [http://hdl.handle.net/10807/68473]

Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis

Rocca, Bianca;Patrono, Carlo;
2015

Abstract

Contemporary medicine is shifting towards person rather than disease-oriented care.1With increasing life expectancy and the ageing of baby boomers, the proportion over 60 years is growing faster than the overall population, with worldwide estimates reaching 2 billion by 2050 (http://www.un.org/esa/population/publications/ worldageing19502050).2 In parallel, acute coronary syndromes (ACS) and atrial fibrillation (AF)—the most frequent indications for dual platelet inhibition or anticoagulation—occur mostly in older patients.2 – 6 There is general agreement that people ≥75 years can be defined ‘elderly’; however, cutoffs as low as 65 years have been applied to important clinical datasets and risk scores.3,7 – 10
Inglese
Andreotti, F., Rocca, B., Husted, S., Ajjan, R., Ten Berg, J., Cattaneo, M., Collet, J., De Caterina, R., Fox, K., Halvorsen, S., Huber, K., Hylek, E., Lip, G., Montalescot, G., Morais, J., Patrono, C., Verheugt, F., Wallentin, L., Weiss, T., Storey, R., Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis, <<EUROPEAN HEART JOURNAL>>, 2015; 36 (46): 3238-3249. [doi:10.1093/eurheartj/ehv304] [http://hdl.handle.net/10807/68473]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/68473
Citazioni
  • ???jsp.display-item.citation.pmc??? 50
  • Scopus 170
  • ???jsp.display-item.citation.isi??? 155
social impact